Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2016; 22(25): 5678-5693
Published online Jul 7, 2016. doi: 10.3748/wjg.v22.i25.5678
New trends in molecular and cellular biomarker discovery for colorectal cancer
Parisa Aghagolzadeh, Ramin Radpour
Parisa Aghagolzadeh, Ramin Radpour, Department of Clinical Research, University Hospital of Bern, 3010 Bern, Switzerland
Author contributions: Aghagolzadeh R and Radpour R wrote the paper.
Conflict-of-interest statement: There is no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ramin Radpour, PhD, Department of Clinical Research, University Hospital of Bern, Murtenstrasse 35, 3010 Bern, Switzerland. ramin.radpour@dkf.unibe.ch
Telephone: +41-31-6320956 Fax: +41-31-6323297
Received: March 21, 2016
Peer-review started: March 22, 2016
First decision: May 12, 2016
Revised: May 16, 2016
Accepted: June 15, 2016
Article in press: June 15, 2016
Published online: July 7, 2016
Processing time: 104 Days and 19.7 Hours
Core Tip

Core tip: Colorectal cancer (CRC) is one of the most common leading causes of cancer death in the world; therefore, any attempt in early diagnosis, selection of appropriate therapeutic strategies and efficient follow up can play an important role in reducing the disease related mortalities. Our review highlights the novel trends and approaches in CRC biomarker discovery, which are categorized as pathologic genetic or epigenetic changes within the tumor tissue as well as non-invasive biomarkers such as blood or stool based markers. These biomarkers could be used for the management of cancer patients.